Moreover, in a retrospective analysis of tumor samples from the BOLERO-2 study, where patients with HR+/HER2-negative advanced disease resistant to an aromatase inhibitor, the proportion of HER2-E in primary vs. metastatic tumors was 19 vs. 32% (41). Here, ERBB2 is linked to neoplasm.